How Investors Are Reacting To Alkermes (ALKS) Strong Alixorexton Orexin-2 Data And Broader CNS Ambitions

Simply Wall St.

Apr 27

Alkermes recently shared new phase 2 Vibrance-1 data for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 1, reporting clinically meaningful, statistically significant improvements in...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2630136275"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630136275\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630136275?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-27 17:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630136275","market":"nz","top_or_hot":-1,"title":"How Investors Are Reacting To Alkermes (ALKS) Strong Alixorexton Orexin-2 Data And Broader CNS Ambitions","media":"Simply Wall St.","content":"<div>\n<p>Alkermes recently shared new phase 2 Vibrance-1 data for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 1, reporting clinically meaningful, statistically significant improvements in...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/how-investors-are-reacting-to-alkermes-alks-strong-alixorext\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors Are Reacting To Alkermes (ALKS) Strong Alixorexton Orexin-2 Data And Broader CNS Ambitions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors Are Reacting To Alkermes (ALKS) Strong Alixorexton Orexin-2 Data And Broader CNS Ambitions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-27 17:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/how-investors-are-reacting-to-alkermes-alks-strong-alixorext><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alkermes recently shared new phase 2 Vibrance-1 data for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 1, reporting clinically meaningful, statistically significant improvements in...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/how-investors-are-reacting-to-alkermes-alks-strong-alixorext\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4135","symbol_name":"资产管理与托管银行","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/how-investors-are-reacting-to-alkermes-alks-strong-alixorext","article_id":"2630136275","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/how-investors-are-reacting-to-alkermes-alks-strong-alixorext","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630136275","pubTimestamp":1777280844,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Alkermes recently shared new phase 2 Vibrance-1 data for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 1, reporting clinically meaningful, statistically significant improvements in wakefulness, cognition and fatigue over 13 weeks with no serious treatment-emergent adverse events, and presented these findings at the 2026 American Academy of Neurology meeting.\nAlongside fresh evidence that LYBALVI may help address difficult-to-treat negative symptoms in schizophrenia, these...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4135":"资产管理与托管银行","CNS":"科恩-斯蒂尔斯金融","BK4211":"区域性银行","ISBC":"投资者银行","ALKS":"阿尔凯默斯","BK4139":"生物科技"},"translate_title":"投资者对Alkermes(ALKS)强劲的Alixorexton Orexin-2数据和更广泛的CNS雄心有何反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALKS":1.5,"ISBC":1.5,"CNS":1.5},"content_text":"Alkermes recently shared new phase 2 Vibrance-1 data for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 1, reporting clinically meaningful, statistically significant improvements in wakefulness, cognition and fatigue over 13 weeks with no serious treatment-emergent adverse events, and presented these findings at the 2026 American Academy of Neurology meeting. Alongside fresh evidence that LYBALVI may help address difficult-to-treat negative symptoms in schizophrenia, these alixorexton results strengthen Alkermes’ neuroscience portfolio and highlight how orexin-targeted and antipsychotic therapies could broaden and extend its central nervous system treatment reach. We’ll now examine how the stronger orexin 2 receptor data for alixorexton may influence Alkermes’ existing investment narrative around its sleep franchise. The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementAlkermes Investment Narrative RecapTo own Alkermes, you really have to believe its focused neuroscience portfolio can offset patent and pricing pressure by turning alixorexton and LYBALVI into durable, cash‑generating brands. The new Vibrance‑1 data and upcoming Brilliance phase 3 program sharpen the near term catalyst around alixorexton, but they also heighten the key risk: Alkermes is spending heavily on orexin without yet knowing if late stage results and regulators will support broad commercial use. Among the latest announcements, the publication of 56 week LYBALVI data on negative symptoms in schizophrenia stands out next to the alixorexton update. Together, these datapoints keep the core neuroscience story front and center, while also reminding investors that Alkermes is leaning on a relatively narrow set of assets at a time when R&D, debt service from the new US$1,525,000,000 credit facility, and regulatory needs are all moving higher. Yet beneath the encouraging orexin results, investors should still weigh the possibility that rising alixorexton R&D and future pricing pressure could... Read the full narrative on Alkermes (it's free!)Alkermes' narrative projects $2.1 billion revenue and $238.9 million earnings by 2029. This requires 11.8% yearly revenue growth and a modest earnings decrease of about $2.8 million from $241.7 million today.Uncover how Alkermes' forecasts yield a $44.24 fair value, a 33% upside to its current price.Exploring Other PerspectivesALKS 1-Year Stock Price Chart You can see how wide opinions run here: before this news, the most optimistic analysts were still only modeling about US$1.7 billion of revenue and US$276 million of earnings by 2028, yet they already viewed alixorexton as a major swing factor that could either justify a much richer valuation or, if late stage data disappoints, expose how concentrated Alkermes really is.Explore 5 other fair value estimates on Alkermes - why the stock might be worth over 2x more than the current price!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Alkermes research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.Contemplating Other Strategies?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Find 54 companies with promising cash flow potential yet trading below their fair value.Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}